KEVIN BITTERMAN

Kevin Bitterman stands as a distinguished Partner at Atlas Venture, a premier venture capital firm renowned for its significant contributions to the biotechnology and life sciences sectors. At Atlas Venture, Kevin is instrumental in the firm's unique company creation model, actively participating in the founding, incubation, and strategic development of new therapeutic companies from their inception. His work is central to identifying unmet medical needs and building innovative solutions to address them.

Kevin's investment focus is sharply honed on early-stage life sciences, with a particular emphasis on drug discovery and the creation of novel therapeutic platforms. He is deeply involved in the scientific and strategic aspects of company building, working closely with entrepreneurs and scientists to transform cutting-edge research into viable biotech ventures. His expertise spans various therapeutic areas, always with an eye toward disruptive technologies and transformative medicines.

Before joining Atlas Venture in 2017, Kevin honed his skills and insights at Third Rock Ventures, where he served as an Associate and Senior Associate. This experience provided him with a robust foundation in venture capital and company formation within the life sciences. Prior to his venture capital career, Kevin gained valuable industry experience in business development at Warp Drive Bio, a company focused on genomic mining for drug discovery. His academic background is equally impressive, holding a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT) and a B.S. in Chemical Engineering from the University of Massachusetts Amherst. This strong scientific and engineering foundation underpins his analytical approach to evaluating new opportunities.

Throughout his career at Atlas Venture, Kevin Bitterman has been a key player in the creation and growth of numerous successful biotech companies. His notable contributions include involvement with companies such as Kallyope, a neuroscience company; Kymera Therapeutics, a leader in targeted protein degradation; Synlogic, focused on synthetic biology; Celsius Therapeutics, exploring functional genomics; and Disarm Therapeutics, which was acquired by Eli Lilly. He has also been involved with Quench Bio (acquired by AbbVie), Triana Biomedicines, and MOMA Therapeutics, among others. These ventures exemplify his commitment to fostering innovation and delivering impactful therapeutic solutions to patients worldwide. Kevin Bitterman's strategic vision and hands-on approach continue to drive significant advancements in the biotech landscape.